Introduction
The 2009 flu pandemic is a global outbreak of a new strain of an influenza A virus subtype H1N1, referred to as the "novel H1N1," first identified in Mexico in April 2009. 1 Since then, the disease spread to all continents, and in June 2009, The World Health Organization (WHO) raised the pandemic alert level to Phase 6. 2 Till December 11, 2009, more than 207 countries had reported laboratory-confirmed cases of pandemic influenza H1N1 2009, including at least 8,768 deaths. 3 In Malaysia, the total number of deaths reported was 77. 4 Clinicians face a great challenge in treating patients with influenza A complicated by ARDS, who require ventilation, as some of these cases do not seem to respond well to conventional therapy. Hence, trials of new modalities of treatment and researches on the pathophysiology of ARDS associated with influenza A are essential in improving treatment outcome. Here, we report the case of a patient who was successfully treated with antiviral therapy, mechanical ventilation, and intravenous immunoglobulin G (IV IgG), even though he was initially given a bad prognosis.
A 59-year-old male patient presented to the district hospital in August 2009 with a history of high-grade fever and sore throat for 4 days. Apart from the fever, he complained of tiredness, reduced appetite, and difficulty in breathing, 2 days before presentation. There was no diarrhea, vomiting, cough, runny nose, or body ache. He has no known prior medical illness.
At the district hospital, the patient was treated for pneumonia, but on Day 3 of admission, the patient's condition deteriorated. He was then transferred to this hospital for further management. On arrival, he was tachypneic, dehydrated, and restless; respiratory rate was 40 breaths/min; temperature was 39.5 C; oxygen saturation was 86e88% on room air and 92e93% on high-flow mask; blood pressure was 177/72 mmHg; and pulse rate was 93 beats/min. Examination of the respiratory system revealed generalized crepitations, no rhonchi, and equal breath sound in both lungs. Examinations of the cardiovascular, abdominal, and neurological systems were unremarkable.
Laboratory tests revealed that the arterial blood gas on high-flow mask showed compensated hypoxia with P a O 2 of 57.9 mmHg and O 2 saturation of 92.5%; the white cell count was 4.38 Â 10 9 /L (neutrophil, 77.1%; lymphocyte, 17.1%; monocyte, 5.3%; eosinophil, 0.0%; basophil 0.5%). Chest radiograph showed bibasal consolidation. Other investigation results are shown in Table 1 . The patient was immediately sent to the intensive care unit and intubated and ventilated with the diagnosis of influenza-like illness and differential diagnosis of community-acquired pneumonia. He was started on oral oseltamivir 150 mg twice daily, IV ceftriaxone 2 g immediately and 1 g daily, and IV azithromycin 500 mg daily.
Despite adequate treatment with double dose of oseltamivir, antibiotic administration, and no evidence of secondary infection, the patient's condition worsened, as evidenced by the ventilator setting change from synchronized intermittent mandatory ventilation to BiLevel mode on Day 4 of admission, with FiO 2 of 0.5, high/low positive end expiratory pressure of 28/12 mmHg, and pO 2 of only 79 mmHg on Day 6 of admission, and serial chest radiographs showed worsening opacity up to the upper zone (Fig. 1) . Blood culture and sensitivity taken on the day of admission grew Gram-positive cocci coagulaseenegative staphylococcus (sensitive to ampicilin, erythromycin, fusidic acid, gentamycin, penicillin, oxacillin, and trimethoprinesulfamethoxazole), endotracheal culture and sensitivity was negative. Real-time polymerase chain reaction result eventually showed novel flu A H1N1 swine lineage, and with the symptoms, he fulfilled the WHO criteria for the diagnosis of a confirmed case of pandemic (H1N1) 2009. 5 On Day 6 of admission, the decision was made to administer 36 g IV IgG (patient's weight was 90 kg) for a planned duration of 5 days. This was the first patient in this hospital who was treated with IV IgG for ARDS secondary to H1N1. After 3 days, the patient showed encouraging response with improvement of ventilator setting (Table 1) . He was extubated on Day 2 postcompletion of IV IgG (Day 19 of illness) and discharged after 20 days of admission. On subsequent follow-up in the outpatient clinic 2 months later, his functional status was back to normal, and his chest radiograph revealed minimal pulmonary fibrosis (Fig. 1) .
Discussion
Intravenous immune globulin (IVIG) contains the pooled IgG immunoglobulins (antibodies) extracted from the plasma of more than 1,000 blood donors. The precise mechanism by which IVIG suppresses harmful inflammation has not been definitively established but is believed to involve the inhibitory Fc receptor. 6, 7 The donor antibody may bind directly with the abnormal host antibody, stimulating its removal. Alternatively, the massive quantity of antibody may stimulate the host's complement system, leading to enhanced removal of all antibodies, including the harmful ones. IVIG also blocks the antibody receptors on immune cells (macrophages), leading to decreased damage by these cells, or regulation of macrophage phagocytosis. IVIG may also regulate the immune response by reacting with a number of membrane receptors on T cells, B cells, and monocytes that are pertinent to autoreactivity and induction of tolerance to self. 8 In 2003, Morishima T 9 from Japan reported that a combination of antivirals, high-dose gamma-grobulin, steroid pulse therapy, high-dose Antithrombin III, head cooling, and plasma exchange, could reduce the mortality of pediatric patients with influenza-associated encephalopathy. Satoshi H 10 et al. demonstrated that high-dose IVIG (1,000 mg/kg) decreased the mortality and pulmonary pathology in a rat model of sepsis.
Despite the fact that data regarding IVIG in severe H1N1 infections was limited, one study had reported significant neutralizing activity of human IVIG preparations against the pandemic H1N1 virus. 11 Another observation by researchers was the association of low total immunoglobulin subclass levels, particularly IgG2, in both pregnant and nonpregnant H1N1 2009 patients who developed respiratory failure. 12 In management of this case, IV IgG was administered on the basis of its potential immune-modulator properties and neutralizing antibodies, which may partly contribute to a favorable outcome of this patient.
In conclusion, this patient was successfully treated with a combination of 0.4 g/kg IV IgG and double dose of oseltamivir. Patients with H1N1 associated with ARDS may be given a trial of IV IgG. More case reports and trials are required to ALP Z alkaline phosphatase; ALT Z alanine aminotransferase; AST Z aspartate transaminase; CPAP Z continuous positive airway pressure; FiO 2 Z fraction of inspired oxygen; NPO 2 Z nasal prong oxygen; PEEP Z positive end expiratory pressure; SIMV Z synchronized intermittent mandatory ventilation; SpO 2 Z oxygen saturation; VM40 Z venture mask 40%; VM60 Z venture mask 60%.
ascertain the efficacy of IV IgG and the best dosage and timing of starting IV IgG in relation to antiviral therapy.
